Core Insights - Eton Pharmaceuticals is participating in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025, in New York, where its executive leadership will host 1x1 meetings [1] Company Overview - Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases, currently offering eight commercial products for rare diseases [3] - The company's commercial products include KHINDIVI™, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3] - Eton has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [3]

Core Insights - Eton Pharmaceuticals reported a strong third quarter in 2025, with product sales increasing by 129% year-over-year, reaching $22.5 million, marking the 19th consecutive quarter of sequential growth [2][5][14]. Financial Performance - The company achieved a net revenue of $22.5 million for Q3 2025, compared to $10.3 million in the same period last year, reflecting an increase of 118% [14]. - Gross profit for the quarter was $7.9 million, up from $6.3 million in the prior year, representing a 25% increase [17]. - Adjusted EBITDA for Q3 2025 was $2.9 million, compared to $2.0 million in the prior year [22]. - The net loss for the quarter was $1.9 million, or $0.07 per diluted share, compared to a net income of $0.6 million, or $0.02 per diluted share, in the prior year [22][23]. Product Performance - The relaunch of INCRELEX significantly contributed to revenue, being the largest revenue contributor in Q3 2025, with strong adoption and awareness efforts [6][9]. - ALKINDI SPRINKLE and Carglumic Acid also showed strong year-over-year growth, supported by a dedicated sales force [11]. - The company is preparing for the launch of ET-600, with its New Drug Application accepted by the FDA and a PDUFA date set for February 25, 2026 [3][13]. Strategic Initiatives - Eton is focusing on expanding the KHINDIVI label and has received positive feedback from the FDA regarding a revised formulation aimed at younger patients [12]. - The company is pursuing harmonization of SPIGFD definitions between the U.S. and EU to increase patient access [6][8]. - Eton's cash position as of September 30, 2025, was $37.1 million, with $12.0 million generated from operations during the quarter [24]. Market Position - Eton Pharmaceuticals is positioned as an innovative company in the rare disease treatment market, with a portfolio of eight commercial products and five additional candidates in late-stage development [28].

Core Viewpoint - Eton Pharmaceuticals, Inc. will report its third quarter 2025 financial results on November 6, 2025, and will host a conference call to discuss these results [1]. Company Overview - Eton Pharmaceuticals is focused on developing and commercializing treatments for rare diseases, currently offering eight commercial products for rare diseases [3]. - The company's commercial products include KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3]. - Eton has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector [3]. Investor Engagement - Management will take live questions during the conference call and will also answer emailed questions from investors [2]. - The live webcast of the conference call will be accessible on Eton's website, with an archived version available for 30 days after the event [2].

Group 1 - Eton Pharmaceuticals, Inc is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases [3] - The company currently has eight commercial rare disease products, including KHINDIVI™, INCRELEX, and Nitisinone [3] - Eton has five additional product candidates in late-stage development, such as ET-600 and ZENEO hydrocortisone autoinjector [3] Group 2 - Eton's executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference from September 3-5, 2025 in Boston, MA [1] - Interested parties can schedule a meeting by contacting their Wells Fargo institutional sales representative [2]

Company Overview - Eton Pharmaceuticals, Inc is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases [3] - The company currently has eight commercial rare disease products, including KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3] - Eton has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector [3] Upcoming Financial Results - Eton Pharmaceuticals will report its second quarter 2025 financial results on August 7, 2025 [1] - Management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results [1] - Investors can submit questions via email during the conference call [1]

Company Overview - Eton Pharmaceuticals, Inc is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases [3] - The company currently has seven commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3] - Eton has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [3] Upcoming Events - Eton's CEO, CFO, and Chief Business Officer will participate in two upcoming investor conferences [1] - The 25th Annual B. Riley Securities Investor Conference is scheduled for May 22, 2025, at 11:15 am ET in Marina Del Rey, California [5] - The 22nd Annual Craig-Hallum Institutional Investor Conference will take place on May 28, 2025, in Minneapolis, Minnesota [5]

Core Viewpoint - Eton Pharmaceuticals, Inc. will report its first quarter 2025 financial results on May 13, 2025, and will host a conference call to discuss these results [1]. Company Overview - Eton Pharmaceuticals is focused on developing and commercializing treatments for rare diseases, currently offering seven commercial products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3]. - The company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector [3]. Investor Relations - Investors can submit questions via email to investorrelations@etonpharma.com during the conference call [1]. - The live webcast of the conference call will be accessible on Eton's website, with an archived version available for 30 days post-event [2].